212631-67-9

212631-67-9 structure

Name: PD184161
Chemical Name: 5-bromo-2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide
CAS Number: 212631-67-9
Molecular Formula: C₁₇H₁₃BrClF₂IN₂O₂
Molecular Weight: 557.556
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2018-06-12 16:59:22
Modify Date: 2024-01-21 21:07:23
PD184161 is an orally active MEK inhibitor. PD184161 inhibits MEK activity (IC50=10-100 nM) in a time- and concentration-dependent manner. PD184161 inhibits cell proliferation and induces apoptosis. PD184161 produces depressive-like behavior[1][2].

Name	5-bromo-2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide
Synonyms	Benzamide, 5-bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro- 5-Bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide hms3263a07 PD 184161

Description	PD184161 is an orally active MEK inhibitor. PD184161 inhibits MEK activity (IC50=10-100 nM) in a time- and concentration-dependent manner. PD184161 inhibits cell proliferation and induces apoptosis. PD184161 produces depressive-like behavior[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> MAPK/ERK Pathway >> MEK Research Areas >> Neurological Disease
Target	MEK:10-100 nM (IC50)
In Vitro	PD184161 (1-20 μM; 24, 48, or 72 hours) inhibits cell proliferation and induces apoptosis in a time and concentration dependent manner[1]. PD184161 (0.1 and 1.0 μM; 1 hour) inhibits ERK1,2 phosphorylation[1]. PD184161 (5 μM; 30 min) prevents the toxic effects of bicuculline[3]. Cell Proliferation Assay[1] Cell Line: HCC cell lines (HepG2, Hep3B, PLC, and SKHep) Concentration: 1-20 μM Incubation Time: 24, 48, or 72 hours Result: Inhibited cell proliferation. Apoptosis Analysis[1] Cell Line: HCC cell lines (HepG2, Hep3B, PLC, and SKHep) Concentration: 1-20 μM Incubation Time: 48 hours Result: Induced cell apoptosis. Western Blot Analysis[1] Cell Line: HCC cell lines (HepG2, Hep3B, PLC, and SKHep) Concentration: 0.1 and 1.0 μM Incubation Time: 1 hours Result: Inhibited ERK1,2 phosphorylation. Cell Viability Assay[3] Cell Line: Primary mouse neurons Concentration: 5 μM Incubation Time: 30 min Result: Prevents the toxic effects of bicuculline.
In Vivo	PD184161 reduces tumor xenograft P-ERK levels in 3-12 hours after an oral dose[1]. PD184161 (300 mg/kg; orogastric gavage twice daily for 38 days) significantly suppresses tumor engraftment and initial growth[1]. PD184161 (30 mg/kg; i.p.; single injection) produces depressive-like behavior[2]. PD184161 (500 μg/kg; intravenous injection) prevents the progression of neurological deficits and brain damage after stroke[3]. Animal Model: Hep3B tumor xenografts BALB/c athymic nude mice[1] Dosage: 300 mg/kg Administration: Orogastric gavage twice daily for 38 days Result: Decreased the early tumor growth. Animal Model: Male, 6 weeks C57Bl/6 mice[2] Dosage: 500 μg/kg Administration: intravenously in 30 min before MCAO or PTZ administration Result: Prevented the progression of neurological deficits and brain damage after stroke. Animal Model: C57Bl/6 mice[3] Dosage: 30 mg/kg Administration: i.p., single injection Result: Produced depressive-like behavior.
References	[1]. Klein PJ, et al. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia. 2006 Jan;8(1):1-8. [2]. Duman CH, et al. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry. 2007 Mar 1;61(5):661-70. [3]. Gladbach A, et al. ERK inhibition with PD184161 mitigates brain damage in a mouse model of stroke. J Neural Transm (Vienna). 2014 May;121(5):543-7.

Density	1.9±0.1 g/cm3
Molecular Formula	C₁₇H₁₃BrClF₂IN₂O₂
Molecular Weight	557.556
Exact Mass	555.886169
PSA	50.36000
LogP	9.28
Index of Refraction	1.670

Symbol	GHS09
Signal Word	Warning
Hazard Statements	H400
Precautionary Statements	P273
RIDADR	UN 3077 9 / PGIII

56-41-7	108-65-6
56-35-9	64-17-5
67-56-1	108-88-3
141-78-6	1310-73-2
13463-67-7	1333-86-4